Skip to content
RDL Network logo
LBP-029-YI Spatial transcriptomics of the tumor microenvironment discriminates inflamed tumors responsive or resistant to atezolizumab + bevacizumab in patients with advanced HCC — Marta Piqué‐Gili (2025) | RDL Network